EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C29H38N2O6 |
| Net Charge | 0 |
| Average Mass | 510.631 |
| Monoisotopic Mass | 510.27299 |
| SMILES | [H][C@]1(c2ccc(OC)cc2)[C@H](C(=O)O)[C@@]([H])(c2ccc3c(c2)OCO3)CN1CC(=O)N(CCCC)CCCC |
| InChI | InChI=1S/C29H38N2O6/c1-4-6-14-30(15-7-5-2)26(32)18-31-17-23(21-10-13-24-25(16-21)37-19-36-24)27(29(33)34)28(31)20-8-11-22(35-3)12-9-20/h8-13,16,23,27-28H,4-7,14-15,17-19H2,1-3H3,(H,33,34)/t23-,27-,28+/m1/s1 |
| InChIKey | MOTJMGVDPWRKOC-QPVYNBJUSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Chemical Roles: | Bronsted base A molecular entity capable of accepting a hydron from a donor (Brønsted acid). Bronsted acid A molecular entity capable of donating a hydron to an acceptor (Brønsted base). |
| Biological Role: | endothelin A receptor antagonist A endothelin receptor antagonist is a drug which selectively blocks endothelin A receptors. |
| Applications: | endothelin A receptor antagonist A endothelin receptor antagonist is a drug which selectively blocks endothelin A receptors. nephroprotective agent Any protective agent that is able to prevent damage to the kidney. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| atrasentan (CHEBI:135810) has role endothelin A receptor antagonist (CHEBI:51452) |
| atrasentan (CHEBI:135810) has role nephroprotective agent (CHEBI:76595) |
| atrasentan (CHEBI:135810) is a benzodioxoles (CHEBI:38298) |
| atrasentan (CHEBI:135810) is a monocarboxylic acid (CHEBI:25384) |
| atrasentan (CHEBI:135810) is a monomethoxybenzene (CHEBI:25235) |
| atrasentan (CHEBI:135810) is a pyrrolidinecarboxylic acid (CHEBI:46767) |
| atrasentan (CHEBI:135810) is a pyrrolidines (CHEBI:38260) |
| atrasentan (CHEBI:135810) is a tertiary amino compound (CHEBI:50996) |
| atrasentan (CHEBI:135810) is a tertiary carboxamide (CHEBI:140326) |
| IUPAC Name |
|---|
| (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid |
| INNs | Source |
|---|---|
| atrasentan | WHO MedNet |
| atrasentán | WHO MedNet |
| atrasentanum | WHO MedNet |
| atrasentan | WHO MedNet |
| Synonyms | Source |
|---|---|
| (2R, 3R, 4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid | ChEBI |
| ABT-627 | DrugBank |
| ABT 627 | DrugBank |
| ABT627 | DrugBank |
| (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid | ChEBI |
| A-147627 | ChEBI |
| Manual Xrefs | Databases |
|---|---|
| Atrasentan | Wikipedia |
| DB06199 | DrugBank |
| Registry Numbers | Sources |
|---|---|
| CAS:173937-91-2 | ChEBI |
| Citations |
|---|